<DOC>
	<DOCNO>NCT00350181</DOCNO>
	<brief_summary>To evaluate incidence grade II-IV acute GVHD sirolimus mycophenolate mofetil GVHD prophylaxis .</brief_summary>
	<brief_title>Sirolimus Mycophenolate Mofetil Graft Versus Host Disease Prophylaxis Myeloablative Matched Related Donor Hematopoietic Cell Transplant</brief_title>
	<detailed_description>To explore novel combination sirolimus mycophenolate mofetil ( MMF ) graft versus host disease ( GVHD ) prevention HLA match related donor blood marrow transplantation ( BMT ) . This study report toxicity associate drug combination also explore possible correlation specific blood cell type antibody production therapy .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Diagnoses Included : 1 . Acute myelogenous leukemia ( AML ) : Age 260 year beyond 2nd remission relapsed/refractory disease . Age 5160 year age , first subsequent remission relapsed/refractory disease AML multilineage dysplasia 2 . Acute lymphoblastic leukemia ( ALL ) : Age 260 year beyond 2nd remission relapsed/refractory disease Age 5160 year first subsequent remission relapsed/refractory disease 3 . Chronic myelogenous leukemia ( CML ) , beyond 2nd chronic phase blast crisis 4 . Myelodysplastic syndrome ( MDS ) include patient World Health Organization ( WHO ) refractory anemia excess blasts1 ( RAEB1 ) , RAEB2 therapyrelated MDS 5 . Myeloproliferative disorder poor long term survival include myeloid metaplasia myelofibrosis 6 . Nonhodgkin lymphoma ( NHL ) High risk NHL first remission Relapsed refractory NHL 7 . Hodgkin lymphoma beyond first remission Other 1 . Patients 260 year age 2 . Matched related donor identify , 6/6 HLAA , B DRB1 3 . Karnofsky performance status &gt; = 70 % Lansky performance status &gt; = 70 % patient &lt; 16 year old . 4 . Willingness ability take oral medication pill form transplantation period . 5 . Informed consent 1 . Prior myeloablative , allogeneic autologous HCT . 2 . HIV infection 3 . Pregnant lactate patient 4 . Evidence uncontrolled active infection 5 . Renal function : serum creatinine &gt; 1.5 mg/dl 24 hour creatinine clearance &gt; 50 ml/min . 6 . Hepatic function : direct bilirubin , ALT AST &gt; 2 x upper limit normal 7 . Pulmonary function : In adult , correct diffusing capacity ( DLCO ) &lt; 60 % predicted child , room air oxygen saturation &lt; 92 % . 8 . Cardiac function : In adult , leave ventricular ejection fraction &lt; 45 % child , shorten fraction &lt; 26 % . 9 . Fasting Cholesterol &gt; 300 mg/dl Triglycerides &gt; 300 gm/dl lipidlowering agent . 10.Patients receive investigational drug unless clear Principal Investigator . 11 . Patients prior malignancy except basal cell carcinoma treat carcinoma insitu . Cancer treat curative intent &gt; 5 year allow . Cancer treat curative intent 5 year allow without Protocol Chair approval .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>